AN2 Therapeutics (ANTX) Long-Term Investments (2021 - 2025)

AN2 Therapeutics (ANTX) has 5 years of Long-Term Investments data on file, last reported at $2.0 million in Q4 2025.

• Long-Term Investments for Q4 2025 came in at $2.0 million, down 59.91% year-over-year; the trailing twelve-month figure through Dec 2025 was $2.0 million (down 59.91% YoY), and the FY2025 annual result was $2.0 million, down 59.91% from the prior year.
• Long-Term Investments declined to $2.0 million in Q4 2025 per ANTX's latest filing, from $3.2 million in the prior quarter.
• Over five years, Long-Term Investments peaked at $27.2 million in Q4 2023 and troughed at $2.0 million in Q3 2022.
• A 5-year average of $8.2 million and a median of $3.7 million in 2021 frame the typical range for Long-Term Investments.
• The sharpest annual moves came in 2023 and 2024: Long-Term Investments jumped 1223.09% in 2023, then tumbled 81.54% in 2024.
• A 5-year view of Long-Term Investments shows it stood at $3.5 million in 2021, then slipped by 7.66% to $3.2 million in 2022, then soared by 744.8% to $27.2 million in 2023, then plunged by 81.54% to $5.0 million in 2024, then plunged by 59.91% to $2.0 million in 2025.
• Business Quant data shows ANTX's Long-Term Investments at $2.0 million in Q4 2025, $3.2 million in Q3 2025, and $8.3 million in Q2 2025.